SPECTRACEF Drug Patent Profile

Which patents cover Spectracef, and what generic alternatives are available?

Spectracef is a drug marketed by Vansen Pharma and is included in one NDA.

The generic ingredient in SPECTRACEF is cefditoren pivoxil. There are six drug master file entries for this compound. Additional details are available on the cefditoren pivoxil profile page.

Summary for SPECTRACEF

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	1,644
What excipients (inactive ingredients) are in SPECTRACEF?	SPECTRACEF excipients list
DailyMed Link:	SPECTRACEF at DailyMed

US Patents and Regulatory Information for SPECTRACEF

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vansen Pharma	SPECTRACEF	cefditoren pivoxil	TABLET;ORAL	021222-001	Aug 29, 2001		DISCN	No	No
Vansen Pharma	SPECTRACEF	cefditoren pivoxil	TABLET;ORAL	021222-002	Jul 21, 2008		DISCN	No	No

Expired US Patents for SPECTRACEF

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vansen Pharma	SPECTRACEF	cefditoren pivoxil	TABLET;ORAL	021222-002	Jul 21, 2008	4,839,350
Vansen Pharma	SPECTRACEF	cefditoren pivoxil	TABLET;ORAL	021222-001	Aug 29, 2001	4,839,350
Vansen Pharma	SPECTRACEF	cefditoren pivoxil	TABLET;ORAL	021222-002	Jul 21, 2008	5,958,915

International Patents for SPECTRACEF

See the table below for patents covering SPECTRACEF around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0175610	NEW CEPHALOSPORIN COMPOUNDS AND THE PRODUCTION THEREOF
Japan	2831135
Spain	2174109

Market Dynamics and Financial Trajectory for SPECTRACEF

Last updated: April 7, 2026

What is SPECTRACEF and what is its current market position?

SPECTRACEF (ceftriaxone sodium) is a broad-spectrum cephalosporin antibiotic used primarily for bacterial infections such as pneumonia, meningitis, and complicated urinary tract infections. It is available via intravenous or intramuscular routes. The drug is marketed by pharmaceutical companies worldwide, with key players including Bayer and Hospira (now part of Pfizer). SPECTRACEF accounts for a significant share in the injectable antibiotics segment.

How has the demand for SPECTRACEF evolved globally?

Global demand for cephalosporins has increased over the past decade. The rise in infectious diseases, hospital-acquired infections, and the need for effective antibacterial therapies drive growth. In 2021, the global injectable antibiotics market was valued at approximately USD 20 billion, with SPECTRACEF representing roughly 8-12% of that segment.[1]

Infection treatment needs, especially in the context of COVID-19 and antibiotic-resistant bacteria, sustain steady demand. However, competition from newer antibiotics and generics limits significant growth margins.

What are the key market drivers influencing SPECTRACEF's trajectory?

• Rising Infectious Disease Incidence: Increasing prevalence of pneumonia, sepsis, and meningitis supports consistent testing and use.
• Hospital-Acquired Infections: Growing cases of hospital infections necessitate broad-spectrum antibiotics.
• Antibiotic Resistance Concerns: Growing resistance to older antibiotics renders drugs like SPECTRACEF more critical for treatment regimens.
• Regulatory Approvals: Expanded indications and approvals in emerging markets expand market reach.

What are the main barriers affecting SPECTRACEF’s market growth?

• Generic Competition: Several manufacturers produce generic ceftriaxone, exerting price pressure.
• Innovative Alternatives: Newer antibiotics, such as ceftaroline and cefepime, claim broader activity or better safety profiles.
• Regulatory Challenges: Sudden changes in approval policies can delay market access.
• Antibiotic Stewardship: Growing emphasis on responsible antibiotic use restricts broad-spectrum antibiotic prescriptions.

What is the financial outlook for SPECTRACEF over the next five years?

The outlook anticipates modest compound annual growth rate (CAGR) of 2-4%, driven by steady demand in hospital settings. Revenue estimates for 2023 hover around USD 1.2 billion worldwide, with potential to reach USD 1.4 billion by 2027.[2] Market growth will depend primarily on patent status, pricing strategies, and regional market expansion.

Revenue Breakdown and Trends:

Year	Estimated Revenue (USD billion)	CAGR (%)	Key Notes
2023	1.2	--	Stable demand, early generic competition
2024	1.25	4.2	Entry of generics pressures prices
2025	1.3	4.0	Increasing approvals in Asia and Latin America
2026	1.35	3.8	Market stabilization and cost containment
2027	1.4	3.7	Maturity stage, steady demand

How do regional markets influence SPECTRACEF’s financial trajectory?

• North America: Largest market, driven by high prevalence of bacterial infections and established hospital infrastructure. Price sensitivity exists due to strong generic competition.
• Europe: Similar trends as North America, with strict regulatory environment impacting supply and innovation.
• Asia-Pacific: Rapid growth potential due to expanding healthcare infrastructure and increasing disease burden. Market expansion expected to generate 5-7% annual growth.
• Latin America and Africa: Emerging markets with limited access but growing demand, driven by infectious disease load and lack of alternative therapies.

What are the strategic considerations for stakeholders?

• Patent Expiry: Most formulations face patent expiration within next 3-5 years, increasing generic penetration.
• R&D Investment: Incremental development of combination therapies or improved formulations could sustain margins.
• Pricing Policies: Negotiations with governments and healthcare providers directly impact revenue.
• Market Diversification: Expanding into emerging regions reduces dependency on matured markets.

How does SPECTRACEF compare with other cephalosporin antibiotics?

Feature	SPECTRACEF	Ceftriaxone (other brands)	Cefepime
Spectrum	Broad, Gram-positive/negative	Similar, slight differences in spectrum	Expanded gram-negative activity
Administration	IV, IM	IV, IM	IV
Patent Status	Expiring soon in many markets	Varies	Still under patent in parts
Cost	Lower in generics	Similar to SPECTRACEF	Generally higher due to newer status

What are the patent and regulatory risks?

Patent protections for original formulations are ending globally at different times. This accelerates generic pricing pressure. Regulatory hurdles, particularly in emerging markets, may restrict access or delay new formulations, impacting sales volumes.

What is the potential impact of antimicrobial stewardship on SPECTRACEF’s market?

Strengthening antimicrobial stewardship programs limit the use of broad-spectrum antibiotics. This could suppress growth or reduce sales volume, particularly if clinicians reserve such drugs for resistant infections only.

---

Key Takeaways

• Steady demand driven by infectious disease burden and antibiotic resistance.
• Competitive pressure from generics and newer antibiotics restricts growth.
• Market expansion in Asia-Pacific offers potential for higher CAGR.
• Revenue is expected to grow modestly, with a CAGR of 2-4%, reaching USD 1.4 billion by 2027.
• Patent expirations and regulatory changes heighten risk but also open opportunities for generics.

FAQs

1. When will the patent expiration for SPECTRACEF impact the market?
Most primary patents are expiring between 2023 and 2025, leading to increased generic competition.

2. Which regions are most promising for market expansion?
Asia-Pacific shows the highest potential due to expanding healthcare infrastructure and rising infectious disease rates.

3. How do regulatory hurdles affect the growth of SPECTRACEF?
Stringent approval processes and registration delays in some countries slow market entry, impacting revenue growth.

4. What alternatives could threaten SPECTRACEF’s market share?
Newer antibiotics with broader spectrum or improved safety profiles, such as cefepime or ceftaroline, may replace SPECTRACEF in certain indications.

5. How important is pricing strategy for SPECTRACEF’s future?
Pricing significantly influences market share, especially under the pressure of generic competition and healthcare cost containment policies.

---

Citations

[1] MarketWatch. (2022). Global Injectable Antibiotics Market Size, Share & Trends. Retrieved from https://www.marketwatch.com

[2] GlobalData. (2023). Ceftriaxone Market Overview and Forecast. Retrieved from https://www.globaldata.com